Upstream Bio, Inc. (UPB)
$3.55-14.87%Close
SELLCRISIS · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $193M
- Beta
- 1.39
- P/E (TTM)
- -1.22
- Short % float
- 22.48%
- Days to cover
- 7.7
- SI change
- +0.5%
- 1W
- -22.66%
- 1M
- -38.90%
- vs SPY 1W
- -23.08%
- vs SPY 1M
- -40.96%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 8
- GROWTH
- 19
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-29.0%
REV YoY-
ROE-48.4%
EPS YoY-
ROA-55.7%
GROSS98
OP-5383
NET-4956
[VALUATION]
P/E TTM-1.22
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.71
P/FCF-
EV/EBITDA-0.73
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.35
ALTMAN Z-
CURR RATIO27.99
ND/EBITDA-
BETA1.39
Company news
FAQ
- What is LOPJLB’s current signal on UPB?
- LOPJLB’s latest quantitative signal on Upstream Bio, Inc. (UPB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is UPB in?
- Upstream Bio, Inc. (UPB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Upstream Bio, Inc. (UPB) do?
- Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively develo…